In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status - KIVIRID

In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status

Authors: Marat Fudim, Harriette G.C. Van Spall

Published: 2022-10-03

DOI: 10.7326/j22-0075

Source: Full article

Abstract

No abstract found.